Corteva completes the Vylor spin-off: seed and crop protection are now two listed companies
Vylor began trading on the NYSE on 1 October with a $19 billion technology pipeline and a licensing arm carrying published targets.
Vylor (NYSE: VYLR), described in its own announcement as an advanced seed and genetics company, said on 1 October 2026 from Johnston, Iowa that it had completed its separation from Corteva Inc. and would begin trading later the same day. Corteva distributed one Vylor share for every Corteva share held by stockholders of record as of 24 September 2026, a pro rata stock dividend intended to be tax-free for US federal income tax purposes. Corteva continues to trade on the NYSE as CTVA. Vylor shares ended their first session higher, AgNavigator reported.
Vylor set out financial targets alongside the completion. It is aiming for net sales of roughly $11.2 billion to $11.9 billion by 2029 on 3 to 4 per cent annual growth, and operating EBITDA of roughly $3.3 billion to $3.7 billion by 2029. The Vylor One licensing business is expected to deliver more than $500 million in gross licensing income in 2027, more than $1 billion by 2035 and approaching $2 billion by 2040. “Vylor was created to reimagine agriculture,” said Vylor chief executive Chuck Magro. “Our ambition is to work with farmers of all sizes to solve some of the world's toughest challenges, food security to energy security, and in the process, help farmers and communities thrive.”
Behind those numbers sits what the company calls a $19 billion technology pipeline, anchored by 12 technology platform launches in corn, soy and wheat over the next decade. Seven new corn platforms are scheduled to start in 2028 and four new soybean platforms to launch by 2035. Xpedite, the system used to create Vylor's proprietary hybrid wheat, is due to launch in North America in late 2027, with the company citing multi-year research trials on the hybrid wheat's yield and yield stability.
What remains inside Corteva is a standalone crop protection business led by chief executive Luke Kissam. Corteva expects to launch 12 new crop protection products over the next decade, including five biologicals, generating roughly $4 billion in peak revenue, according to AgNavigator. “This is a new day for Corteva, and we couldn't be more excited as we move forward with greater focus, agility and a renewed commitment to innovation and operational excellence,” Kissam said in comments reported by the same outlet.
Why it matters for AgTech founders: the single largest partner in row-crop inputs has become two, with two balance sheets, two boards and two sets of published numbers to hit. That changes the pitch. A trait, breeding or gene-editing company no longer sells into one strategic conversation that could land anywhere in a conglomerate; it now has to decide whether its technology belongs in a seed and genetics P&L or a chemistry P&L, because the other side will not stretch across the fence to buy it. The sharper signal is Vylor One. Licensing with a published 2027 number and a 2040 trajectory is licensing that someone is now measured on, which makes an in-licensing deal a realistic path to revenue rather than a polite meeting, and it also sets the terms: a counterparty with that target will want germplasm-adjacent technology that scales across acres, not a point solution. On the Corteva side, five biologicals inside a 12-product pipeline is a small, specific window for biologicals startups, and a narrower company is usually a more motivated buyer. The timing caveat is ordinary and worth planning around: companies in their first quarters as standalones are busy with separation costs, systems and their own guidance, so business development cycles typically stretch before they shorten.
Corteva completes the Vylor spin-off: seed and crop protection are now two listed companies
Vylor began trading on the NYSE on 1 October with a $19 billion technology pipeline and a licensing arm carrying published targets. Corteva keeps crop protection. AgTech founders now have two counterparties where there was one.
Vylor (NYSE: VYLR), described in its own announcement as an advanced seed and genetics company, said on 1 October 2026 from Johnston, Iowa that it had completed its separation from Corteva Inc. and would begin trading later the same day. Corteva distributed one Vylor share for every Corteva share held by stockholders of record as of 24 September 2026, a pro rata stock dividend intended to be tax-free for US federal income tax purposes. Corteva continues to trade on the NYSE as CTVA. Vylor shares ended their first session higher, AgNavigator reported.
Vylor set out financial targets alongside the completion. It is aiming for net sales of roughly $11.2 billion to $11.9 billion by 2029 on 3 to 4 per cent annual growth, and operating EBITDA of roughly $3.3 billion to $3.7 billion by 2029. The Vylor One licensing business is expected to deliver more than $500 million in gross licensing income in 2027, more than $1 billion by 2035 and approaching $2 billion by 2040. “Vylor was created to reimagine agriculture,” said Vylor chief executive Chuck Magro. “Our ambition is to work with farmers of all sizes to solve some of the world's toughest challenges, food security to energy security, and in the process, help farmers and communities thrive.”
Behind those numbers sits what the company calls a $19 billion technology pipeline, anchored by 12 technology platform launches in corn, soy and wheat over the next decade. Seven new corn platforms are scheduled to start in 2028 and four new soybean platforms to launch by 2035. Xpedite, the system used to create Vylor's proprietary hybrid wheat, is due to launch in North America in late 2027, with the company citing multi-year research trials on the hybrid wheat's yield and yield stability.
What remains inside Corteva is a standalone crop protection business led by chief executive Luke Kissam. Corteva expects to launch 12 new crop protection products over the next decade, including five biologicals, generating roughly $4 billion in peak revenue, according to AgNavigator. “This is a new day for Corteva, and we couldn't be more excited as we move forward with greater focus, agility and a renewed commitment to innovation and operational excellence,” Kissam said in comments reported by the same outlet.
Why it matters for AgTech founders: the single largest partner in row-crop inputs has become two, with two balance sheets, two boards and two sets of published numbers to hit. That changes the pitch. A trait, breeding or gene-editing company no longer sells into one strategic conversation that could land anywhere in a conglomerate; it now has to decide whether its technology belongs in a seed and genetics P&L or a chemistry P&L, because the other side will not stretch across the fence to buy it. The sharper signal is Vylor One. Licensing with a published 2027 number and a 2040 trajectory is licensing that someone is now measured on, which makes an in-licensing deal a realistic path to revenue rather than a polite meeting, and it also sets the terms: a counterparty with that target will want germplasm-adjacent technology that scales across acres, not a point solution. On the Corteva side, five biologicals inside a 12-product pipeline is a small, specific window for biologicals startups, and a narrower company is usually a more motivated buyer. The timing caveat is ordinary and worth planning around: companies in their first quarters as standalones are busy with separation costs, systems and their own guidance, so business development cycles typically stretch before they shorten.
